Alzheimer's Researchers Say the Field Has Been Asking the Wrong Question
For decades, the dominant strategy in Alzheimer's drug development has been elegant in theory: identify a single culprit, deploy a precise intervention, halt the disease. That approach has produced drugs like lecanemab and donanemab—treatments that generated headlines and hope—but none that reverse the underlying destruction or restore lost cognitive function. Now, a comprehensive review argues the entire framework needs to change.
The Paper That Changes Everything
Publishing in Science China Life Sciences, a team led by Professor Yan-Jiang Wang synthesizes evidence that Alzheimer's disease arises not from one rogue process, but from a tangled web of molecular breakdowns, genetic predispositions, and systemic failures that unfold over years before symptoms ever appear.
The paper, titled "Advances in Alzheimer's disease: mechanistic insights and therapeutic targets," contends that the field's fixation on individual pathways—particularly the amyloid-beta plaques that have dominated research for thirty years—has obscured a more complicated reality.
Four Interconnected Domains
The review identifies four interconnected domains that researchers must address simultaneously.
Amyloid-Beta and Tau
Amyloid-beta remains relevant but insufficient on its own. The limited clinical gains from anti-amyloid therapies have pushed scientists toward also targeting tau protein tangles, which correlate more tightly with cognitive decline.
Genetic Vulnerability
Genetics shape risk in ways that vary across populations. The well-known APOE ε4 variant explains only part of the risk, and the authors point to CRISPR-based genome editing as a potential one-time intervention.
Aging as a Disease Driver
Aging itself acts as a disease driver through mitochondrial dysfunction, cellular senescence, and accumulated DNA damage. This finding has spawned interest in "senolytic" treatments designed to clear aged cells from the brain.
Systemic Health
The rest of the body matters. Insulin resistance, hypertension, and disruptions in the gut microbiome all influence how quickly Alzheimer's progresses, opening the door to repurposing diabetes medications and other systemic approaches.
The authors call for abandoning "reductionist" thinking—the search for one key mechanism—in favor of integrated strategies that combine multiple interventions. They advocate for using human stem-cell-derived organoids to test drug combinations before clinical trials, and for guiding treatment decisions with biomarkers like plasma pTau217, which can signal disease activity years before memory problems become obvious.
Success in defeating Alzheimer's hinges on interdisciplinary collaboration and holistic innovation. The team's ambition extends beyond managing symptoms to the possibility of prevention—a goal that remains distant but, they argue, no longer theoretical.
Based on: "Advances in Alzheimer's disease: mechanistic insights and therapeutic targets"; Yan-Jiang Wang et al.; Science China Life Sciences, 2025. DOI: 10.1007/s11427-025-2991-7.